More recently, Plummer et al. have demonstrated the efficacy of E7449 (PARP/tankyrase inhibitor) in patients with solid tumours, including CRC, showing a promising antitumoral activity with 50–800 mg oral dose. Here, PARP1 is linked to colorectal carcinoma.